Dysfunction of the p53 tumor suppressor pathway in head and neck cancer

被引:1
|
作者
Hoque, MO
Kawamata, H
Nakashiro, KI
Omotehara, F
Hino, S
Uchida, D
Harada, K
Begum, NM
Yoshida, H
Sato, M
Fujimori, T
机构
[1] Dokkyo Univ, Sch Med, Dept Surg & Mol Pathol, Shimotsuga, Tochigi 3210293, Japan
[2] Univ Tokushima, Sch Dent, Dept Oral & Maxillofacial Surg 2, Tokushima 7708504, Japan
关键词
head and neck cancer; p53; p33ING1; p14ARF; p21WAF1;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is important to examine the abnormality of the entire p53 tumor suppressor pathway in head and neck cancer. We examined the mRNA expressions of p53 regulatory factors, p33ING1 and p14ARF, and a p53-target gene, p21WAF1 in head and neck cancer, Nine of 14 benign pleomorphic adenomas (PAs) and 7 of 8 malignant salivary gland tumors (MSGTs) expressed p33ING1 mRNA. Thirteen of 14 PAs expressed p14ARF mRNA, however, only I of 8 MSGTs expressed p14ARF mRNA. Eight of 14 PAs and 7 of 8 MSGTs expressed p21WAF1 mRNA. In salivary gland tumors, there was clear correlation between the expression of p33ING1 and p21WAF1 (p<0.0001, r(2)=0.53). However, there was no correlation between the expression of p14ARF and p21WAF1 (p=0.6543, r(2)=0.009). Twenty-six of 28 oral squamous cell carcinomas (SCCs) expressed p33ING1 mRNA. Nineteen of 28 oral SCCs expressed p14ARF mRNA. All of the oral SCCs expressed p21WAF1 mRNA. In oral SCCs, the expressions of both p33ING1 (p=0.009, (r(2)=0.181) and p14ARF(p=0.0009, r(2)=0.271) correlated with the expression of p21WAF1. Interestingly, 24 of 26 oral SCCs (92%) showed either abnormality of p53 itself or loss of expression of p53 regulatory factors, p33ING or p14ARF. These results suggest that head and neck cancer often involve the dysfunction of p53 tumor suppressor pathway.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 50 条
  • [11] Requirement of the ATM/p53 Tumor Suppressor Pathway for Glucose Homeostasis
    Armata, Heather L.
    Golebiowski, Diane
    Jung, Dae Young
    Ko, Hwi Jin
    Kim, Jason K.
    Sluss, Hayla K.
    MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (24) : 5787 - 5794
  • [12] Tumor suppressor p53 and metabolism
    Liu, Juan
    Zhang, Cen
    Hu, Wenwei
    Feng, Zhaohui
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 284 - 292
  • [13] The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer
    Götte, K
    Riedel, F
    Neubauer, J
    Schäfer, C
    Coy, JF
    Hörmann, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (02) : 331 - 336
  • [14] CARF: An emerging regulator of p53 tumor suppressor and senescence pathway
    Cheung, Caroline T. Y.
    Hasan, Md. Kamrul
    Widodo, Nashi
    Kaul, Sunil C.
    Wadhwa, Renu
    MECHANISMS OF AGEING AND DEVELOPMENT, 2009, 130 (1-2) : 18 - 23
  • [15] APOPTOSIS, CANCER AND THE P53 TUMOR-SUPPRESSOR GENE
    LEE, JM
    BERNSTEIN, A
    CANCER AND METASTASIS REVIEWS, 1995, 14 (02) : 149 - 161
  • [16] Tumor suppressor p53 and its mutants in cancer metabolism
    Liu, Juan
    Zhang, Cen
    Hu, Wenwei
    Feng, Zhaohui
    CANCER LETTERS, 2015, 356 (02) : 197 - 203
  • [17] Manipulation of the tumor suppressor p53 for potentiating cancer therapy
    Haupt, S
    Haupt, Y
    SEMINARS IN CANCER BIOLOGY, 2004, 14 (04) : 244 - 252
  • [18] Alterations in p53 tumor suppressor gene in lung cancer
    Zalcman, G
    Soussi, T
    REVUE DES MALADIES RESPIRATOIRES, 2000, 17 (01) : 329 - 349
  • [19] Therapeutic strategies for head and neck cancer based on p53 status (Review)
    Ota, Ichiro
    Okamoto, Noritomo
    Yane, Katsunari
    Takahashi, Akihisa
    Masui, Takashi
    Hosoi, Hiroshi
    Ohnishi, Takeo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (04) : 585 - 591
  • [20] P53 genotyping - An effective concept for molecular testing of head and neck cancer?
    Dahse, R
    Fieldler, W
    Von Eggeling, F
    Schimmel, B
    Koscielny, S
    Beleites, E
    Claussen, U
    Ernst, G
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1999, 4 (03) : 279 - 283